LBS 007

Drug Profile

LBS 007

Alternative Names: LBS-007

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Columbia University Medical Center; Memorial Sloan-Kettering Cancer Center
  • Developer Columbia University Medical Center; Lin Bioscience; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Mar 2017 LBS 007 licensed to Lin Biosciences
  • 03 Mar 2017 Preclinical trials in Haematological malignancies in USA (unspecified route)
  • 03 Mar 2017 Lin BioScience plans a phase I trial for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top